I n normal physiology, the open-ended lymphatic vascular system drains extravasated interstitial fluid from peripheral tissue and returns it to the blood via the thoracic duct. 1 In addition, the lymphatics absorb dietary fat in the intestine and assist in immune surveillance by allowing antigen-presenting cells to migrate through lymphatic vessels to reach lymph nodes (LNs) for antigen presentation to T and B lymphocytes. 2, 3 In pathology, lymphatics play a substantial role in conditions such as chronic inflammation, 4 tumor growth, and metastasis. [5] [6] [7] However, despite the growing interest in lymphatic biology, the molecular mediators of lymphatic vessel function have remained poorly characterized. In ontogeny, the prevalent theory is that lymphatic vessels originate from a subset of venous endothelial cells in the anterior cardinal vein that express the homeobox transcription factor Prox-1 around embryonic (E) 9.5 of mouse development and subsequently commit to the lymphatic endothelial cells (LEC) lineage. 8 These cells sprout to form the primary lymph sacs. Peripheral lymphatic vessels form by centrifugal sprouting from the primary lymph sacs and form a network, followed by maturation of large collecting lymphatic vessels. Identifi-cation of lymphatic endothelial-specific markers present in developing lymphatic vessels, such as Prox-1, podoplanin, 9 and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), 10 has advanced the study of lymphatic cells during the past decade. Although these markers distinguish lymphatic endothelium from blood endothelium in the adult, some proteins are common to both blood and lymphatic endothelium, such as the surface receptors vascular endothelial growth factor receptor 2 (VEGFR-2) and VEGFR-3. 11 Interestingly, VEGFR-3 is expressed on the blood and lymphatic endothelium during development 12 and is restricted to lymphatics in the adult. 13 In addition to known roles for the originally identified ligands (vascular endothelial growth factor [VEGF]-C and VEGF-D), 14, 15 lymphatic growth is also stimulated by VEGF-A in several experimental systems, and the activation of its receptor, VEGFR-2, seems to be required for LEC organization into functional capillaries. 16 -18 Furthermore, VEGF-A/C-VEGFR-2/3 pathways have also been shown to be involved in the pathological formation of lymphatic vessels. 19, 20 However, intracellular signaling mediators remain poorly characterized.
Bone marrow tyrosine kinase in chromosome X (Bmx; also called endothelial/epithelial tyrosine kinase [Etk] ) is a member of the Tec family of nonreceptor tyrosine kinases. Members of the Tec kinase family (Bmx, Btk, Itk, Rlk, and Tec) constitute the second largest family of nonreceptor tyrosine kinases. They share common structural domains including a pleckstrin homology domain, a Tec homology domain, a Src homology domain-3 (SH3), an SH2 domain, and a kinase domain 21 Despite some redundancy, specific roles for each member of this family have been identified using genetically deficient mice. Bmx-deficient mice (Bmx-KO) are viable and do not display any obvious developmental defects. 22 However, on pathological insult using an ischemia hindlimb model, Bmx-KO mice had reduced arteriogenesis and angiogenesis that led to decreased clinical recovery, limb perfusion, and ischemic reserve capacity relative to control mice. 23, 24 The role of Bmx in lymphatic endothelium is unknown. In the present study, we show that Bmx is expressed in mouse LEC in vivo and in human lymphatic endothelial cells (HLEC), isolated from human skin. By inhibiting Bmx in HLEC, we reveal that Bmx is involved in lymphangiogenic responses induced by VEGF-A and VEGF-C. More importantly, our results from Bmx-KO elucidate a role of Bmx in lymphangiogenesis in 2 mouse models. Our data suggest that Bmx directly contributes to lymphatic remodeling in vivo by regulating VEGF-A/Cdependent signaling pathways.
Methods
The detailed materials and methods are provided in the online supplement, available online at http://atvb.ahajournals.org. These methods include mouse cornea lymphangiogenesis assay, histology and immunohistochemistry, lymphatic endothelial cell (EC) culture, tube formation assay and immunoblotting for Bmx-VEGFR2/3 signaling. These methods have previously been used for angiogenesis assays. 23, 25 
Results

Bmx Is Upregulated in Lymphatic Vessels by VEGF and Contributes to VEGF-Induced Lymphangiogenesis
Although Bmx is specifically expressed in aortas/arteries in normal physiology, we have previously shown that Bmx is highly induced in capillaries of ischemic tissues and is critical for inflammatory angiogenesis. 23 One of many factors produced during chronic inflammation is VEGF. VEGF has been shown to induce lymphangiogenesis in several experimental systems. 16 -18 We used Bmx-deficient mice to determine the role of Bmx in VEGF-induced lymphangiogenesis by systemic delivery of adenovirus expressing VEGF-A. Bmx was expressed at a low level in lymphatic vessels of unstimulated wild-type (WT) LNs. However, Bmx was highly induced by VEGF in LYVE-1-positive lymphatic vessels ( Figure 1A ). Expression of Bmx was luminal, whereas expression of LYVE-1 was on the abluminal side of the vessel, as has previously been described for LYVE-1. 26 As controls, Bmx was not detected in Bmx-KO mice (Supplemental Figure Ia) or mice receiving LacZ adenovirus (not shown). Expression of Bmx showed a similar pattern in platelet endothelial cell adhesion molecule-1 (PECAM-1)-positive blood vessels (Supplemental Figure Ib) . Quantitative analyses indicated that VEGF-induced lymphangiogenesis in LN was significantly reduced in Bmx-KO mice relative to WT mice ( Figure  1B , with quantification in Figure 1C ). Similar results were obtained for the role of Bmx in VEGF-induced LN angiogenesis (Supplemental Figure Ib 
VEGF-Induced Cornea Lymphangiogenesis Is Attenuated in Bmx-KO Mice
The mammalian cornea is one of only a few avascular tissues. Pathological corneal lymphangiogenesis has been reported to occur in response to various growth factors, including 2 members of the VEGF family of proteins (VEGF-A and VEGF-C). 27, 28 Therefore, we sought to determine the role of Bmx in this model of lymphangiogenesis by implantation of a Hydron pellet containing VEGF-A or VEGF-C recombinant proteins into the cornea of WT and Bmx KO mice. Compared with saline controls, both growth factors stimulated growth of new blood vessels. Neovascularization induced by VEGF-A and VEGF-C was detected around day 7 (Figure 2A quantification in Figure 2B ). Sprouting from the preexisting corneal limbus was observed and was visualized by stereomicroscopy. VEGF-C induced a stronger lymphangiogenic response relative to VEGF-A ( Figure 2C , with quantification in Figure 2D ), as identified by LYVE-1 staining. Interestingly, lymphangiogenesis could be detected on day 7 and peaked on day 14 postimplantation in WT mice, when newly generated blood vessels started to regress (not shown). These LYVE-1-positive vessels were larger (diameter) vessels compared with newly developed LYVE-1-negative PECAM-1-positive blood vessels. Most importantly, VEGF-A and VEGF-Cinduced lymphatic vessels in WT mice were longer, showed more sprouting, and covered more area than those induced in the Bmx-KO mice ( Figure 2C , with quantification in 2D). These results support a role for Bmx in lymphangiogenesis in VEGF-A and VEGF-C induced cornea lymphangiogenesis.
Bmx Mediates VEGF Signaling and Function in HLEC
To determine the mechanism by which Bmx mediates VEGFinduced lymphangiogenesis, we first examined Bmx expression in purified HLEC obtained from 2 independent sources (see Supplemental Materials and Methods). For characterization, cells were stained with Prox-1 and podoplanin, which are nuclear and transmembrane markers for HLEC, respectively. Earlier passage cells were Ͼ95% positive for LEC markers. These markers were not expressed by human um- bilical vein endothelial cells (HUVEC) (data not shown), nor detected using IgG controls (Supplemental Figure IIa) . However, HUVEC and HLEC were positive for the blood vascular lineage markers PECAM-1 (data not shown). All experiments were performed in early passages (passages 3 to 6), and cells remained Prox-1 positive. Next, we examined whether Bmx is expressed in HLEC by immunofluorescence microscopy and Western blot with anti-Bmx antibody. Bmx was expressed in the cytoplasm of HLEC obtained from both independent sources (Clonetics cells shown in Supplemental Figure IIa ). Western blot showed that Bmx (75 kDa) expression was detected in HLEC and HUVEC (Supplemental Figure IIb) . We also examined expression of VEGF receptors that are important for lymphangiogenesis. As expected, HUVEC expressed both VEGFR-1 and VEGFR-2. However, HLEC expressed VEGFR-3 and VEGFR-2 but not VEGFR-1, as has been reported for LECs 29 (Supplemental Figure IIb) . The specificity of the Bmx antibody was confirmed by Western blot using control and Bmx knockdown HLEC (Supplemental Figure IIc) . Interestingly, we did not detect Bmx induction in HLEC by VEGF at both short and long treatments (Supplemental Figure IIc and IId, respectively). This is in contrast to the observed in vivo induction of Bmx by VEGF, suggesting that Bmx upregulation by VEGF is a secondary effect by unknown factor(s). The specificity of anti-VEGFR antibodies was determined by Western blot using cell lysates expressing each individual VEGF receptor (Supplemental Figure IIe) . To our knowledge, this is the first report to show Bmx expression in purified HLEC.
To determine the function of Bmx in HLEC, we first used a short interfering RNA (siRNA) knockdown approach to determine the role of Bmx in VEGF signaling in lymphatic EC. Immunoblots revealed an Ͼ80% decrease of Bmx expression by each individual siRNA (Supplemental Figure  IIIa) or by a combination of the 3 siRNAs ( Figure 3A ). Bmx knockdown was also confirmed by decreased mRNA transcript and did not cause an interferon response compared with parental cells as determined by quantitative PCR for the interferon-responsive genes oligoadenylate synthetase and RNA-dependent protein kinase (Supplemental Figure IIIb) . To investigate a functional role for Bmx, we then determined the effect of Bmx knockdown on the formation of tube-like structures by HLEC in a Matrigel assay in which EC interconnect to form tube like structures, a process known to involve adhesive and migratory events, as well as changes in cell morphology. HLEC tube formation was enhanced by the presence of VEGF-A or VEGF-C, with the greater enhancement using VEGF-C. Knockdown of Bmx in HLEC led to a significant reduction in the ability of HLEC to form tube-like structures in a Matrigel in response to VEGF-C ( Figure 3A , with quantification in 3B). Using a second approach to assess function of Bmx in HLEC, we used an inhibitor of Bmx, LFM-A13. This drug has been shown to block Bmx signaling in HUVEC at a dose of 30 mol/L. 30 Hence, we used this concentration to pretreat HLECs for 1 hour before the Matrigel assay. Similar to the Bmx siRNA, LFM-A13 significantly reduced VEGF-C-induced tube formation ( Figure 3C ) compared with mock (dimethyl sulfoxide [DMSO]), with quantification shown in Figure 3D .
To investigate the signaling mechanisms to explain our in vivo and in vitro lymphangiogenesis observations, we examined the effects of Bmx inhibition on the VEGF signaling. VEGF-A and VEGF-C induced phosphorylation of phospholipase gamma (PLC-␥) and Akt, 2 well-characterized (lymph) angiogenic pathways, as determined by phosphospecific antibodies. Interestingly, VEGF-A and VEGF-C differentially activated these 2 pathways. VEGF-A preferentially induced phosphorylation of PLC-␥, whereas VEGF-C strongly activated Akt ( Figure 3E ). Importantly, Bmx knockdown was able to reduce both VEGF-A and VEGF-C responses in HLEC ( Figure 3E ). To determine whether Bmx kinase activity is necessary for its function in VEGF signaling, we used LFM-A13. Similar to the Bmx siRNA, LFM-A13 significantly inhibited VEGF-A and VEGF-C-induced signaling compared with mock (DMSO) ( Figure 3F ). Taken together, this data provides evidence that Bmx protein and its kinase activity are necessary for VEGF-A/C lymphangiogenic signaling and tube formation in lymphatic EC.
Bmx Differentially Regulates VEGFR-2-and VEGFR-3-Dependent Signaling in HLEC
Differential activation of PLC-␥ and Akt by VEGF-A and VEGF-C in HLEC prompted us to examine activation of upstream receptors. VEGF-A activates VEGFR-2 whereas VEGF-C activates both VEGFR-2 and VEGFR-3. However, a mutant form of VEGF-C (C156S, CS) binds to and activates only VEGFR-3, not VEGFR-2. 31, 32 We first examined the VEGF-receptor signaling in HLEC, which express both VEGFR-2 and VEGFR-3. Similar to HUVEC (Supplemental Figure IVa) , VEGF-A strongly induced phosphorylation of VEGFR-2 ( Figure 4A ). As expected, VEGF-C, but not the VEGF-CS mutant, weakly induced phosphorylation of VEGFR-2. However, VEGF-C and VEGF-CS (but not VEGF-A) induced phosphorylation of VEGFR-3, as determined by a phosphospecific antibody (pY1063/68, phosphorylation sites within the kinase activation loop essential for VEGFR-3 kinase activity [33] [34] [35] [36] ) ( Figure 4A ). We then determined the role of Bmx in VEGFR-2 and VEGFR-3 activation using Bmx siRNA and inhibitor. Bmx siRNA caused a significant decrease in phosphorylation of VEGFR-2 induced by VEGF-A and VEGF-C in HLEC. In contrast, Bmx siRNA did not alter or slightly increased phosphorylation of VEGFR-3 in response to VEGF-C and VEGF-CS ( Figure  4A ). Similar results were obtained from the Bmx inhibitor ( Figure 4B ). These data indicate that Bmx and its kinase activity are required for the activation of VEGFR-2 but not of VEGFR-3.
Because VEGF-C could use both VEGFR-3 homodimer and VEGFR-2/3 heterodimer to transduce the downstream signaling, 36 it was not clear whether or not Bmx had any role in the VEGFR-3-dependent pathway. To determine whether Bmx plays any role in VEGFR-3-dependent signaling, we examined the effects of Bmx siRNA on VEGFR-3-specific signaling. VEGF-CS, like VEGF-C, strongly induced activation of VEGFR3 downstream Akt signaling ( Figure 4C ). Silencing of Bmx revealed complete inhibition of VEGF-CSinduced Akt activation ( Figure 4C ). Taken together, these results suggest that Bmx regulates VEGFR-3-dependent sig- naling downstream of VEGFR-3. However, Bmx may function at a level of the receptor complex in the VEGFR-2 signaling, consistent with our previous observations that VEGFR-2 and Bmx reciprocally activate each other. 24
Bmx via Multiple Domains Strongly Associates With VEGFR-2 in HLEC
The results above prompted us to examine whether Bmx associates with VEGFR-2 in lymphatic EC. To this end, HLEC were untreated or treated with VEGF-A. Association of Bmx with VEGFR-2 was determined by a coimmunoprecipitation assay with anti-Bmx followed by Western blot with anti-VEGFR-2. Association of Bmx with VEGFR-2 was detected in resting HLEC, and VEGF-A had no effects on the association ( Figure 5A ). Bmx contains several structural domains (pleckstrin homology, Tec homology, SH3, SH2, and kinase domains, Figure 5B ). To determine the domain of Bmx responsible for interaction with VEGFR-2, we used FLAG-tagged expression constructs encoding different Bmx structural domains. 37 As shown in Figure 5B , Bmx-K contains the kinase domain only. Bmx-SH3/2 contains the SH2 and SH3 domains. Bmx-PTH contains the pleckstrin homology and Tec homology domains. 293T cells were cotransfected with FLAG-tagged Bmx mutants and VEGFR-2 constructs, and interaction of proteins with VEGFR-2 was performed by coimmunoprecipitation with anti-FLAG followed by Western blot with anti-VEGFR-2. Results showed that multiple domains of Bmx are important for its association with VEGFR-2 ( Figure 5C ).
In a coimmunoprecipitation assay, we could not detect the Bmx-VEGFR-3 complex in either resting or VEGF-C-treated HLEC (not shown). Because the level of endogenous VEGFR-3 is significantly lower compared with VEGFR-2 (see Supplemental Figure II ), we overexpressed VEGFR-3 and Bmx in 293T cells. VEGFR-3 was found to associate with Bmx. We then mapped the critical domains of Bmx for VEGFR-3 binding. Cotransfection of FLAG-tagged Bmx mutants and VEGFR-3 construct show that the SH3/2 domain of Bmx is essential for association with VEGFR-3 ( Figure  5D ). Taken together, these results suggest that Bmx and VEGFR-3 may form a signaling complex to mediate VEGFR-3 signaling downstream of VEGFR-3 phosphorylation ( Figure 5E ).
Discussion
In the present study, we identified Bmx as a novel mediator of inflammatory lymphangiogenesis. We show that Bmx expression in lymphatic vessels can be induced by VEGF, and Bmx-KO mice exhibit reduced VEGF-induced lymphangiogenesis relative to WT mice using in vivo mouse models. Recently, 2 reports have described upregulation of Bmx in tumor growth, 38, 39 consistent with the role of Bmx in cell growth. Expression of Bmx appears to be transient as Bmx levels at 2 weeks after VEGF stimulation in vivo were similar to levels found prestimulation. This is consistent with the idea of Bmx being important for the growth but not for the maintenance of lymphatics. In vitro, Bmx is expressed in human lymphatic EC and plays an important role in the formation of tube-like structures. Mechanistically, we dem- hours, subsequently serum-starved overnight, and then treated with VEGF-A (A; 50 ng/mL), VEGF-C (C; 100 ng/mL), or VEGF-CS(Cys156Ser) (CS; 250 ng/mL) for 5, 10, and 10 minutes, respectively. Phospho-and total VEGFR-2 and VEGFR-3 were determined by Western blot with phosphospecific antibodies. Similar results were obtained from 2 additional experiments. B, The Bmx inhibitor reduces phosphorylation of VEGFR-2 but not VEGFR-3. Parental HLEC were serum starved overnight. Cells were pretreated with DMSO (mock) or a Bmx inhibitor LFM-A13 (30 mol/L) for 1 hour followed by treatment with VEGF (50 ng/mL) or VEGF-C (100 ng/mL) for the indicated times. Phospho-and total VEGFR-2 and VEGFR-3 were determined. Similar results were obtained from 2 additional experiments. C, Bmx mediates VEGFR-3 downstream signaling. HLEC were transfected with a human Bmx siRNA or control siRNA (20 nmol/L) for 24 hours, subsequently serum-starved overnight, and then treated with VEGFR-3-specific ligand VEGF-CS(Cys156Ser) (250 ng/mL) for the indicated times. Phosphoand total Akt were determined. Similar results were obtained from 2 additional experiments.
onstrate that Bmx differentially regulates VEGFR-2 and VEGFR-3 signaling pathways ( Figure 5E , A model for Bmx function in VEGF-A/C signaling): VEGF-A activates VEGFR-2, whereas VEGF-C activates both VEGFR-2 and VEGFR-3. In human lymphatic EC, VEGF-A preferentially induces phosphorylation of PLC-␥. In contrast, VEGF-C preferentially activates Akt. Interestingly, Akt phosphorylation appears to correlate with the lymphangiogenic activity of VEGF-C ( Figure 3 ). Bmx associates with and directly regulates VEGFR-2 activation; however, Bmx mediates VEGFR-3 downstream signaling without an effect on the receptor autophosphorylation. Therefore, Bmx is important in both VEGF-A (via VEGFR-2) and VEGF-C (via both VEGFR-2 and VEGFR-3) mediated lymphangiogenesis. Previous studies of Bmx functions have been restricted to the blood endothelium. Our current study is the first demonstration for a role of Bmx in lymphatic endothelium.
Vascular endothelial growth factors (VEGFs) and their receptors play key roles in angiogenesis and lymphangiogenesis. 2, 3 We observe that human vascular EC (HUVEC) express both VEGFR-1 and VEGFR-2, 2 VEGF receptors involved in angiogenesis. In contrast, human lymphatic EC (HLEC) express VEGFR-3 and VEGFR-2, 2 VEGF receptors critical for lymphangiogenesis. Consistent with previous results, 31, 32 VEGF-A activates VEGFR-2, whereas VEGF-C activates VEGFR-2 and VEGFR-3. By taking an siRNA knockdown approach in HLEC, we demonstrated that Bmx is necessary for maximal responses of both VEGF-A-and VEGF-C-induced signaling cascades, including phosphorylation of VEGFR-2, PLC-␥, and Akt. Other signaling mediators have also been found to be important downstream of VEGFR-2/3 such as small GTPases. 40 Interestingly, RhoA, which is selectively activated by Bmx among the small GTPases, 41 is important for LEC tube formation. 42 Indeed, we detected an increase in an active form of RhoA after stimulation with VEGF-A and VEGF-C (Supplemental Figure Va and Vb). More importantly, we observed a decreased amount of active RhoA after Bmx silencing and inhibition, relative to control (Supplemental Figure Va and Vb). Interestingly, we could detect a basal association of Bmx with VEGFR-2 in resting lymphatic EC. This is similar to our previous finding that Bmx associates with tumor necrosis factor receptor 2 in resting blood EC. 24 The ability of Bmx to bind membrane through its pleckstrin homology domain allows rapid involvement in VEGFR-2/3 related signaling. Additional studies are needed to determine whether Bmx is involved in VEGFR-2/3 cellular trafficking and endocytosis, a critical step in regulating VEGFR-2 activation. 43, 44 Notably, VEGF-C was more active in inducing lymphangiogenesis in vivo (cornea assay) and in vitro (the HLEC tube formation assay) compared with VEGF-A. Relative to VEGF-A, VEGF-C induces a weaker phosphorylation of the VEGFR-2-PLC-␥ axis but shows a stronger activation of VEGFR3-Akt. These results suggest that a robust response of Akt by VEGF-C is likely through VEGFR-3. Importantly, our data support that Bmx, in addition to regulating VEGFR-2, also plays a direct role in VEGF-C/VEGFR-3induced Akt activation. Because Bmx knockdown has no effect on VEGFR-3 phosphorylation, it appears that Bmx mediates VEGFR-3-dependent Akt activation at a point downstream of the receptor activation. It is known that on VEGFR-3 ligand (eg, VEGF-C) binding, autophosphorylation of VEGFR-3 at several tyrosine residues in the intracellular domain results in recruitment of signaling adaptor proteins, such as Src homology-containing protein (Shc) and HLEC were serum-starved and treated with VEGF-A (50 ng/mL for 5 minutes). The association of Bmx with VEGFR-2 was determined by a coimmunoprecipitation assay with anti-Bmx followed by Western blot with anti-VEGFR-2 or anti-Bmx. An isotope of IgG was used as a control. Proteins in the input were determined by Western blot with the respective antibodies. Experiments were repeated twice. B, Schematic diagram for Bmx structural domains and expression constructs. PH indicates the pleckstrin homology domain; TH, Tec homology domain; K: kinase domain; aa, amino acids. C, Bmx via multiple domains binds to VEGFR-2. VEGFR-2 expression plasmid was cotransfected with FLAG-tagged Bmx mutants into 293T cells, and the interaction of Bmx proteins with VEGFR-2 was performed by coimmunoprecipitation with anti-FLAG followed by Western blot with anti-VEGFR-2. VC indicates vector control. D, Bmx via the SH3 and SH2 domains weakly associates with VEGFR-3. VEGFR-3 and FLAG-tagged Bmx mutants were coexpressed in 293T cells, and the interaction of Bmx proteins with VEGFR-3 was performed by a coimmunoprecipitation assay with anti-FLAG followed by Western blot with anti-VEGFR-3. E, A model for the role of Bmx in VEGF-A and VEGF-C signaling. Bmx differentially regulated VEGFR-2 and VEGFR-3-dependent lymphangiogenic pathways. See text for details. growth factor receptor binding protein 2 (Grb-2), inducing the activation of downstream cascades, including phosphatidylinositol 3-kinase/Akt signaling. 34, 35 The exact mechanism by which Bmx mediates Akt activation is not known. Our previous studies demonstrated that Bmx could directly associate with the phosphatidylinositol 3-kinase p85 subunit, transducing tumor necrosis factor receptor 2-dependent Akt activation. 24 It is conceivable that Bmx plays a similar role in VEGFR-3-mediated Akt activation. It has recently been shown that both VEGFR-2 and VEGFR-3 stimulation activates endothelial nitric oxide synthase in LEC. 45 It remains to be determined whether Bmx is important for VEGFR-2/3dependent endothelial nitric oxide synthase activation through activating the Akt pathway.
Previously, we have shown that Bmx is among many genes that play important roles in pathological but not physiological angiogenesis. 23 One reason is that Bmx is normally expressed in aortas/arteries, but ischemia strongly upregulates Bmx expression in angiogenic vessels. 23 Similarly, Bmx-KO have normal lymphatic vasculature in physiological settings compared with WT mice (in LNs and cornea, as we observed). Bmx is not expressed or is only weakly expressed in normal lymphatic vessels, but it is highly induced in response to VEGF. Upregulation of Bmx suggests that Bmx may be directly responsible for lymphangiogenesis by enhancing lymphangiogenic signaling in inflammatory settings. In vitro, VEGF-A or VEGF-C did not significantly enhance Bmx expression (Supplemental Figure II) . It remains to be determined how Bmx expression is regulated by ischemia and VEGF. Furthermore, the incomplete loss of lymphangiogenesis suggests there are other redundant mediators of lymphangiogenesis, but Bmx is necessary for a full response in our models. In summary, we conclude that Bmx is important for maximal adult lymphangiogenesis in using the models described here. Our data provide a new potential therapeutic target for the treatment of human lymphangiogenesisassociated diseases.
